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The clinical value of oestrogen receptor (RE)
determinations in breast cancer has been established
(McGuire et al., 1975; Maynard et al., 1978) and a
recent study has demonstrated the further
importance of quantitative measurements (Campbell
et al., 1981). However, errors in measurement of
receptor value may occur, as shown by inter- and
intra-laboratory variation in values with samples of
the same tumour (Raam et al., 1981). The
inaccuracies of the conventional assay procedure
have been emphasised (Poulson, 1981) yet a recent
study has shown that much observed intra- and
inter-laboratory variation could be attributable to
factors other than assay conditions, such as
heterogeneity of tumour samples (King, 1980).
Although the prognostic significance ofRE almost
certainly relates to the tumour cell fraction rather
than the stromal component, receptor
measurements are performed on homogenate or
cytosol prepared from whole tumour. This is a
further source of potential error but little
information is available concerning the relationship
between measured RE concentration and epithelial
tumour cellularity, since previous studies have used
subjective methods only (Feherty et al., 1971;
Terenius et al., 1974; Rosen et al., 1975; Masters et
al., 1978). The present study investigates the
association between RE concentration (expressed in
mg cytosol protein) and tumour epithelial cellularity
(obtained by an objective histometric method of cell
counting).
Oestrogen receptor assays and cellularity
determinations were performed on primary breast
cancers of 100 consecutive patients who presented
to one surgeon (Prof. R.W. Blamey) between 1978
and 1979. Tumour samples were taken at
mastectomy and all surplus adipose tissue trimmed
off. Specimens were frozen and stored in liquid N2
at -196°C before being transported on dry ice to
the Tenovus Institute, Cardiff where RE assays were
performed by the Dextran-coated charcoal method
(Maynard et al., 1978). Tumours were considered to
be RE-positive when they contained >5 fmol
specific oestradiol binding per mg cytosol protein.
Adjacent tumour blocks were taken and fixed in
10% buffered formalin and paraffin sections were
cut and stained with haematoxylin and eosin.
Tumour epithelial cellularity was assessed by
examination of multiple sections of 4-6 Ilm
thickness on a microscope incorporating an
eyepiece graticule. The graticule had an array of 25
randomly arranged points which appeared
superimposed upon the field under examination
(Figure 1). If N points fall upon tumour cells and M
fall upon non-malignant tissue then the ratio
N/(N +M) is representative of the surface area
proportion occupied by tumour cells in each field.
Using a'magnification of 63 x, fields were counted
systematically, starting with the graticule at the top
left corner of the tumour edge, then moving one full
field horizontally to the right and the process
repeated. At the periphery of the tumours the fields
examined deliberately just overlapped into adjacent
non-tumour tissue in order to provide a comparable
sample to that used for RE measurement. A mean of
87 fields was evaluated in 2-5 sections for each
tumour (range 21-200 fields depending on tumour
size). The total N/(N+M) is representative of the
volume proportion of tumour cells (Delesse, 1848;
Dunnill, 1968). The total ratio was expressed as a
percentage and designated the tumour epithelial
cellularity. A reproducibility study was performed
by re-examining a random sample of 1 in 10 cases,
the counting process being repeated in a vertical
direction. All microscopic cell counts were
performed without knowledge of the RE value for
any tumour.
Oestrogen receptor value in RE-positive tumours
had a lognormal distribution. Pearson's test of
correlation was used and the correlation coefficient
(r) was utilized for calculation of the degree of
interdependence of the variables. When both
receptor positive and negative tumours were
considered in combination, RE measurements had a
non-parametric distribution, and Kendall's rank test
of correlation was used.
(9 The Macmillan Press Ltd., 1983
Correspondence: C.W. Elston
Received 3 December 1982; accepted 15 January 1983
E550 C.J. MUMFORD et al.
Figure 1 Section of a highly cellular tumour with the graticule superimposed. Note that 22/25 points fall on
tumour.
Sixty ofthe 100 patients were postmenopausal and
62 had RE-positive tumours (Table I). Measured
cellularity ranged from 10%-92% (mean, 40%)
(Figure 2). The reproducibility study showed a
mean variation of 2.5%. Mean cellularity was 41%
in RE-positive tumours and 39% in RE-negative
tumours.
Receptor concentrations in RE-positive tumours
ranged from 16.4-979fmolmg-1 cytosol protein.
No relationship between cellularity and RE
concentration was seen in the tumours of
premenopausal patients, nor in the group overall.
However, a significant association was observed
between tumour epithelial cellularity and RE
concentration in the tumours of postmenopausal
women (Tau=0.219; P<0.05), and this relationship
was particularly strong if receptor-positive tumours
only were considered (Pearson r=0.423; P<0.01,
(Figure 3)). In the Pearson test of correlation the
square of the coefficient of correlation, r, equals the
variance (r2=0.185). Thus, 18.5% of the range of
measured receptor concentration is due to variation
in tumour epithelial cellularity.
Table I Relationship between menopausal status of
patients and oestrogen receptor status of their tumours
Oestrogen receptor status
Menopausal oftumour
status Positive Negative Total
Pre- 21 19 40
Post- 41 19 60
Total 62 38 100
Previous studies have used subjective methods to
investigate the relationship between tumour
cellularity and RE concentration in breast cancer.
By dividing cellularity into 3 categories, high,
moderate or low, some authors reported a
correlation between the 2 variables (Terenius et al.,
1974; Masters et al., 1978) but others could not
confirm this (Feherty et al., 1971; Wittliff et al.,
1971). The present study provides evidence by a
reproducible and objective method that such a
relationship exists; approximately one fifth of theCELLULARITY AND OESTROGEN RECEPTOR EXPRESSION 551
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Figure 2 Range of cellularity values in 100 primary
breast carcinomas.
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Figure 3 Relationship between log RE value (fmolmg-1 cytosol protein) and tumour cellularity in RE-
positive tumours from 42 post-menopausal women.
measured range of RE in tumours of
postmenopausal women is due to a variance of
cellularity.
No relationship exists, however, between RE
concentration and cellularity in tumours of
premenopausal women. The range of measured
receptor values is generally lower in premenopausal
patients, due to high circulating levels of plasma
hormone which occupy receptor sites, making them
unavailable for assay (Saez et al., 1978). It is
possible that this factor could conceal a relationship
between cellularity and total receptor concentration.
The importance of quantitative RE values in
prediction of response to therapy has recently been
demonstrated (Campbell et al., 1981). However, a
small proportion of patients with RE-negative
cancers do respond to hormonal measures. It is
conceivable in these instances that receptors were
present in cancer cells, but the concentration in the
cytosol was insufficiently high to be detected by
conventional methods, as a result of low overall
cellularity.
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